natgillin/translations-raw huggingface dataset:
Olaparib does not affect the pharmacokinetics of tamoxifen. 
Olaparib ne vpliva na farmakokinetiko tamoksifena.
No significant interaction was observed with anastrozole or letrozole, whereas tamoxifen decreased exposure to olaparib by 27%. 
Z anastrozolom in letrozolom niso opazili pomembnega medsebojnega delovanja, tamoksifen pa je zmanjšal izpostavljenost olaparibu za 27 %.
A value <1 favours olaparib. 
Vrednost < 1 je v korist olapariba.
Very common side effects that may show up in blood tests: 
Zelo pogosti neželeni učinki, ki se lahko pokažejo na preiskavah krvi:
In the olaparib-treated group, 28.4% of patients remained on treatment for ≥2 years and 14.9% for ≥5 years. 
V skupini, zdravljeni z olaparibom, je 28,4 % bolnic ostalo na zdravljenju ≥ 2 leti in 14,9 % ≥ 5 let.
Lynparza has moderate influence on the ability to drive and use machines. 
Zdravilo Lynparza ima zmeren vpliv na sposobnost vožnje in upravljanja strojev.
Retrospective testing of patients with available tumour samples was performed using central testing and generated successful results in 341 patients, of which 95% had an eligible mutation (known [n=47] or likely pathogenic [n=277]) and 2 gBRCAwt patients were confirmed to have sBRCAm only. 
Retrospektivno testiranje bolnic, za katere so bili na voljo vzorci tumorja, je bilo opravljeno s centralnim testiranjem in je dalo uspešne rezultate pri 341 bolnicah, od katerih jih je 95 % imelo ustrezno mutacijo (znano [n = 47] ali verjetno patogeno [n = 277]) in pri 2 gBRCAwt bolnicah je bilo potrjeno, da imata le sBRCAm.
Other medicines and Lynparza 
Druga zdravila in zdravilo Lynparza
The capsules must be discarded after this period. 
Po preteku tega obdobja je treba kapsule zavreči.
The European Medicines Agency has waived the obligation to submit the results of studies with Lynparza in all subsets of the paediatric population, in ovarian carcinoma (excluding rhabdomyosarcoma and germ cell tumours) (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Lynparza za vse skupine pediatrične populacije pri karcinomu jajčnikov (izključujoč rabdomiosarkom in tumorje kličnih celic) (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
• ergot alkaloids - used to treat migraines and headaches 
• ergot alkaloidi - uporabljajo se za zdravljenje migrene in glavobolov,
PFS2 (31% maturity) 
PFS2 (31 % zrelost)
Vomiting events led to interruption in 10% of olaparib-treated patients; no olaparib-treated patients experienced a vomiting event leading to dose reduction. 
Primeri bruhanja so vodili do prekinitve zdravljenja pri 10 % bolnic, zdravljenih z olaparibom; nobeni od bolnic, zdravljenih z olaparibom, se ni pojavilo bruhanje, ki bi vodilo do zmanjšanja odmerka.
Figure 7 PFS (BICR), Forest plot, by prespecified subgroup 
PFS (BICR), drevesni diagram po vnaprej določenih podskupinah
• cisapride - used to treat stomach problems 
• cisaprid - uporablja se za zdravljenje težav z želodcem,
Data demonstrating clinical validation of tumour BRCA1/2 tests in breast cancer are not currently available. 
Podatkov, ki bi dokazovali klinično veljavnost testov mutacij BRCA1/2 v tumorju pri raku dojk, trenutno ni.
gBRCA1/2 mutation status should be determined by an experienced laboratory using a validated test method. 
Prisotnost mutacije gBRCA1/2 mora ugotoviti izkušen laboratorij z validirano testno metodo.
Dose interruptions occurred most frequently in the first 3 months and dose reductions in the first 3-6 months of treatment. 
Prekinitve uporabe so bili najpogostejši v prvih 3 mesecih zdravljenja in zmanjšanja odmerka so bili najpogostejši v prvih 3 - 6 mesecih zdravljenja.
Age - year (median) 
Starost - leta (mediana)
Anaemia was managed with dose interruptions and dose reductions (see section 4.2), and where appropriate with blood transfusions. 
Anemijo so obravnavali s prekinitvijo uporabe oz. zmanjšanji odmerka (glejte poglavje 4.2) ter s transfuzijami krvi, kjer je bilo to primerno.
Consequently, Lynparza may be taken without regard to food (see section 4.2). 
Zato je mogoče zdravilo Lynparza jemati ne glede na hrano (glejte poglavje 4.2).
In patients with mutations (changes) in certain genes called BRCA (breast cancer gene), who are at risk of developing some forms of cancer, PARP inhibitors are able to trigger the death of cancer cells by blocking an enzyme that helps repair DNA. 
Pri bolnicah z mutacijami (spremembami) posebnih genov, imenovanih "gen raka dojk" (BRCA), ki imajo veliko tveganje za pojav določenih oblik raka, lahko zaviralci PARP sprožijo odmrtje rakavih celic tako, da blokirajo encim, udeležen pri popravljanju DNK.
In BRCA-mutated patients (n=136) there was a statistically significant improvement in PFS, TFST and TSST. 
Pri bolnicah z mutacijo gena BRCA (n = 136) so ugotovili statistično značilno izboljšanje PFS, TFST in TSST.
Frequency of CTCAE grade 3 and above 
Pogostnost vseh stopenj po CTCAE Pogostnost stopenj 3 in več po CTCAE
By central germline testing, deleterious or suspected deleterious mutations were identified in 95.3% (365/383) and 4.7% (18/383) of patients, respectively. 
S centralnim testiranjem germinalne linije so bile škodljive mutacije ugotovljene pri 95,3 % (365/383) in domnevno škodljive pri 4,7 % (18/383) bolnic.
They received an average of 3 previous chemotherapy regimens (range 2-11) and 2.6 previous platinum-containing chemotherapies (range 2-8). 
Prejele so povprečno 3 predhodne sheme kemoterapije (razpon: od 2 do 11) in 2,6 predhodnih kemoterapij na osnovi platine (razpon: od 2 do 8).
Majority of the material was excreted as metabolites. 
Večina materiala se je izločila v obliki presnovkov.
events/patients 
dogodkov/bolnice
Patients were stratified based on: receipt of prior chemotherapy regimens for metastatic breast cancer (yes/no), hormone receptor (HR) positive vs triple negative (TNBC), prior platinum treatment for breast cancer (yes/no). 
Bolnike so stratificirali glede na: prejemanje predhodnih shem kemoterapije za metastatskega raka dojk (da/ne), pozitivni hormonski receptorji (HR) v primerjavi s trojno negativnim rakom dojk (TNBC - triple negative breast cancer) ter predhodno zdravljenje s platino zaradi raka dojk (da/ne).
• a certain type of breast cancer (BRCA-mutated, HER2-negative) which has spread beyond the original tumour. 
• določene vrste raka dojk (HER2-negativen rak dojk z mutacijo gena BRCA), ki se je razširil zunaj prvotnega tumorja.
• low white blood cell count (lymphopenia) which may decrease your ability to fight infection and may be associated with fever 
• majhno število belih krvnih celic v krvi (limfocitopenija), zaradi česar se lahko zmanjša vaša sposobnost za premagovanje okužb in je lahko povezano z vročino,
Information on other ingredients in this medicine This medicine contains less than 1 mmol sodium (23 mg) per 100 mg or 150 mg tablet, that is to say essentially “sodium-free”. 
Informacije o drugih sestavinah tega zdravila To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 100 mg ali 150 mg tableto, kar v bistvu pomeni ‘brez natrija'.
PFS - DCO 30 June 2010 
PFS - DCO 30. junij 2010
Enrolment did not require evidence of BRCA1/2 mutation (BRCA mutation status for some patients was determined retrospectively). 
Za vključitev ni bil potreben dokaz mutacije gena BRCA1/2 (stanje mutacije gena BRCA je bilo pri nekaterih bolnicah določeno retrospektivno).
What Lynparza is and what it is used for What you need to know before you take Lynparza How to take Lynparza 
Kaj je zdravilo Lynparza in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Lynparza Kako jemati zdravilo Lynparza Možni neželeni učinki
Ovarian cancer Lynparza is indicated as monotherapy for the: 
Rak jajčnikov Zdravilo Lynparza je indicirano kot monoterapija za:
Lynparza is supplied in packs containing 56 film-coated tablets (7 blisters of 8 tablets each), or multipacks containing 112 (2 packs of 56) film-coated tablets. 
Zdravilo Lynparza je opremljeno v pakiranjih, ki vsebujejo 56 filmsko obloženih tablet (7 pretisnih omotov, od katerih vsak vsebuje 8 tablet), ali v skupnih pakiranjih, ki vsebuje 112 (2 pakiranji po 56) filmsko obloženih tablet.
The magnitude of the effect of moderate to strong inducers (e.g. efavirenz, rifabutin) on olaparib exposure is not established, therefore the co-administration of Lynparza with these medicinal products is also not recommended (see section 4.4). 
Velikost učinka zmernih do močnih induktorjev (npr. efavirenza, rifabutina) na izpostavljenost olaparibu ni ugotovljena, zato sočasna uporaba zdravila Lynparza s takšnimi zdravili prav tako ni priporočljiva (glejte poglavje 4.4).
Your doctor has prescribed Lynparza capsules for you. 
Zdravnik vam je predpisal kapsule zdravila Lynparza.
Olaparib inhibited UGT1A1 in vitro, however, PBPK simulations suggest this is not of clinical importance. 
Olaparib je in vitro zaviral UGT1A1, toda PBPK-simulacije kažejo, da to ni klinično pomembno.
Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). 
Bolniki morajo biti predhodno zdravljeni z antraciklinom in taksanom v okviru (neo)adjuvantnega zdravljenja ali zdravljenja metastatske bolezni, razen če za ti zdravljenji niso primerni (glejte poglavje 5.1).
In Study 19, 20 patients were identified with a somatic tumour BRCA mutation (a mutation in the tumour but wildtype in the germline). 
V študiji 19 so pri 20 bolnicah ugotovili somatsko tumorsko mutacijo gena BRCA (mutacijo v tumorju, a divji tip v klični liniji).
Data from a double-blind placebo-controlled study showed median increase up to 23% from baseline remaining consistent over time and returning to baseline after treatment discontinuation, with no apparent clinical sequelae. 
Podatki dvojno slepe, s placebom kontrolirane študije so pokazali mediano povečanje do 23 % v primerjavi z izhodiščem, konsistentno skozi čas in z vrnitvijo na izhodišče po prekinitvi zdravljenja, brez opaznih kliničnih posledic.
Lynparza is provided in HDPE plastic bottles containing 112 hard capsules. 
Zdravilo Lynparza je na voljo v plastenkah iz HDPE, ki vsebujejo 112 trdih kapsul.
All patients 
Vse bolnice
90% of patients had creatinine values of CTCAE grade 0 at baseline and 10% were CTCAE grade 1 at baseline. 
90 % bolnic je imelo izhodiščno vrednosti kreatinina po CTCAE 0. stopnje in 10 % 1. stopnje.
Frequencies of occurrence of adverse reactions are defined as: very common (≥1/10); common (1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1000); very rare (<1/10,000); not known (cannot be estimated from available data). 
Pogostnosti neželenih učinkov so opredeljene kot: zelo pogosti (≥ 1/10), pogosti ( 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Very common Fatigue (including asthenia) 
pogosti utrujenost (vključno z astenijo)
Frequencies of occurrence of adverse reactions are defined as: very common (≥ 1/10); common ( 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1000); very rare (< 1/10,000); not known (cannot be estimated from available data). 
Pogostnosti neželenih učinkov so opredeljene kot: zelo pogosti (≥ 1/10), pogosti ( 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Median TSST (months) 
Mediani TSST (meseci)
The primary endpoint was progression-free survival (PFS) defined as time from randomisation to progression determined by investigator assessment using modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, or death. 
Primarni opazovani dogodek je bilo preživetje brez napredovanja bolezni (PFS), opredeljeno kot čas od randomizacije do napredovanja po raziskovalčevi oceni na podlagi modificiranih meril RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) ali do smrti.
Your doctor has prescribed Lynparza film-coated tablets for you. 
Zdravnik vam je predpisal filmsko obložene tablete zdravila Lynparza.
Of the 94 patients on the placebo arm who received subsequent therapy, 49 (52%) received a PARP inhibitor. 
Od 94 bolnic v skupini s placebom, ki so prejele nadaljnje zdravljenje, jih je 49 (52 %) prejelo zaviralec PARP.
Olaparib showed no mutagenic potential, but was clastogenic in mammalian cells in vitro. 
Olaparib ni bil mutagen, se je pa izkazal za klastogenega v celicah sesalcev in vitro.
Patients were stratified by response to first-line platinum chemotherapy; complete response (CR) or partial response (PR). 
Bolnice so stratificirali glede na odziv na kemoterapijo prve linije s platino; popoln odziv (CR - complete response) ali delen odziv (PR - partial response).
What you need to know before you take Lynparza 
Kaj morate vedeti, preden boste vzeli zdravilo Lynparza
Pharmacotherapeutic group: antineoplastic agents, other antineoplastic agents, ATC code: L01XX46 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), druga zdravila z delovanjem na novotvorbe (citostatiki), oznaka ATC: L01XX46
If you forget to take Lynparza, take your next normal dose at its scheduled time. 
Če ste pozabili vzeti zdravilo Lynparza, vzemite naslednji normalni odmerek ob predvidenem času.
The active substance is olaparib. 
Učinkovina je olaparib.
Median PFS (months) 
Mediano PFS (meseci)
Pneumonitis, including events with a fatal outcome, has been reported in <1.0% of patients treated with Lynparza in clinical studies. 
V kliničnih študijah je bil pnevmonitis, vključno s smrtnim izidom, opisan pri < 1,0 % bolnic, ki so bile zdravljene z zdravilom Lynparza.
Based on its mechanism of action (PARP inhibition), Lynparza could cause foetal harm when administered to a pregnant woman. 
Glede na mehanizem delovanja (zavrtje PARP) zdravilo Lynparza lahko škoduje plodu, če se uporablja pri nosečnici.
The duration of therapy with olaparib in patients who developed MDS/AML varied from <6 months to >2 years; data with longer durations of exposure are limited. 
Pri bolnicah, ki so zbolele za MDS/AML, je zdravljenje z olaparibom trajalo od < 6 mesecev do > 2 leti; podatkov o dolgotrajnejši izpostavljenosti je malo.
* (2-sided) 
(2-stranska)
It cannot be excluded that olaparib may increase the exposure to substrates of BCRP (e.g. methotrexate, rosuvastatin), OATP1B1 (e.g. bosentan, glibenclamide, repaglinide, statins and valsartan), OCT1 (e.g. metformin), OCT2 (e.g. serum creatinine), OAT3 (e.g. furosemide and methotrexate), MATE1 (e.g. metformin) and MATE2K (e.g. metformin). 
Ni mogoče izključiti možnosti, da olaparib poveča izpostavljenost BCRP (npr. metotreksatu, rosuvastatinu), OATP1B1 (npr. bosentanu, glibenklamidu, repaglinidu, statinom in valsartanu), OCT1 (npr. metforminu), OCT2 (npr. kreatininu v serumu), OAT3 (npr. furosemidu in metotreksatu), MATE1 (npr. metforminu) in MATE2K (npr. metforminu).
All patients had potential contributing factors for the development of MDS/AML; having received previous chemotherapy with platinum agents. 
Vse bolnice so imele dejavnike, ki so lahko pripomogli k pojavu MDS/AML; predhodno so prejemale kemoterapijo z zdravili s platino.
• pimozide, quetiapine - used to treat mental health problems 
• pimozid, kvetiapin - uporabljata se za zdravljenje težav z duševnim zdravjem,
Some of the patients had a history of previous cancer or of bone marrow dysplasia. 
Nekatere bolnice so imele anamnezo predhodnega raka ali displazijo kostnega mozga.
Lynparza may only be used in patients with severe renal impairment if the benefit outweighs the potential risk, and the patient should be carefully monitored for renal function and adverse events. 
Zdravilo Lynparza se sme pri bolnikih s hudo okvaro ledvic uporabiti le, če koristi odtehtajo možna tveganja; bolnikom je potrebno skrbno spremljati delovanje ledvic in neželene dogodke.
• digoxin, diltiazem, furosemide, verapamil, valsartan - used to treat heart conditions or high blood pressure 
• digoksin, diltiazem, furosemid, verapamil, valsartan - uporabljajo se za zdravljenje bolezni srca ali visokega krvnega tlaka,
• low white blood cell count (leukopenia or neutropenia) which may decrease your ability to fight infection and may be associated with fever. 
• majhno število belih krvnih celic v krvi (levkopenija, nevtropenija), zaradi česar se lahko zmanjša vaša sposobnost za premagovanje okužb in je lahko povezano z vročino.
Symptoms of overdose are not established and there is no specific treatment in the event of Lynparza overdose. 
Simptomi prevelikega odmerjanja niso ugotovljeni zato specifičnega zdravljenja za preveliko odmerjanje zdravila Lynparza ni.
If the blood parameters remain clinically abnormal after 4 weeks of Lynparza dose interruption, bone marrow analysis and/or blood cytogenetic analysis are recommended. 
Če krvne vrednosti ostanejo klinično nenormalne še 4 tedne po prekinitvi uporabe zdravila Lynparza, je priporočljivo opraviti preiskavo kostnega mozga in/ali krvno citogenetsko analizo.
This is because Lynparza can affect the way some other medicines work. 
Zdravilo Lynparza namreč lahko vpliva na delovanje nekaterih drugih zdravil.
Reports of pneumonitis had no consistent clinical pattern and were confounded by a number of pre-disposing factors (cancer and/or metastases in lungs, underlying pulmonary disease, smoking history, and/or previous chemotherapy and radiotherapy). 
Opisani primeri pnevmonitisa niso imeli konsistentnega kliničnega vzorca in so jih spremljali številni predispozicijski dejavniki (rak in/ali metastaze v pljučih, osnovna bolezen pljuč, anamneza kajenja in/ali predhodna kemoterapija ali radioterapija).
• methotrexate - used to treat cancer, rheumatoid arthritis and psoriasis. 
• metotreksat - uporablja se za zdravljenje raka, revmatoidnega artritisa in luskavice.
TFST (58% maturity) Number of events: Total number of patients (%) 
TFST (~58 % zrelost) Število dogodkov: skupno število bolnic (%)
In solutions of purified proteins, the olaparib fraction bound to albumin was approximately 56%, which was independent of olaparib concentrations. 
V raztopinah prečiščenih beljakovin je bil na albumin vezani delež olapariba približno 56 % in ni bil odvisen od koncentracije olapariba.
PFS2 (40% maturity) Number of events: Total number of patients (%) 
PFS2 (~40 % zrelost) Število dogodkov: skupno število bolnic (%)
• at regular intervals decided by your doctor after the first year of treatment. 
• po prvem letu zdravljenja pa v rednih presledkih, ki jih bo določil zdravnik.
Appropriate clinical monitoring is recommended for patients receiving this type of medicinal product concomitantly. 
Bolnike, ki sočasno prejemajo to vrsto zdravil, je priporočljivo ustrezno klinično spremljati.
OUTER CARTON MULTIPACK -including the blue box 
ZUNANJA ŠKATLA SKUPNEGA PAKIRANJA - z modrim okencem
• bosentan - used to treat pulmonary artery hypertension 
• bosentan - uporablja se za zdravljenje pljučne arterijske hipertenzije,
In the event that a patient already receiving Lynparza requires treatment with a strong or moderate CYP3A inducer, the prescriber should be aware that the efficacy of Lynparza may be substantially reduced (see section 4.5). 
Če bolnik, ki že prejema zdravilo Lynparza, potrebuje zdravljenje z močnim ali zmernim induktorjem CYP3A, se mora zdravnik, ki predpisuje zdravilo, zavedati, da se lahko učinkovitost zdravila Lynparza bistveno zmanjša (glejte poglavje 4.5).
A small number of patients treated with Lynparza reported inflammation of the lungs (pneumonitis). 
Pri maloštevilnih bolnicah, ki so jemale zdravilo Lynparza, se je pojavilo vnetje pljuč (pnevmonitis).
• you are taking certain medicines that may affect Lynparza (see section 2). 
• če jemljete določena zdravila, ki lahko vplivajo na delovanje zdravila Lynparza (glejte poglavje 2),
Common side effects that may show up in blood tests: 
Pogosti neželeni učinki, ki se lahko pokažejo na preiskavah krvi:
Exploratory analyses of time to first subsequent therapy or death (TFST) and time to second subsequent therapy or death (TSST- an approximation of PFS2) were also performed. 
Opravljeni sta bili tudi eksploratorni analizi časa do prvega nadaljnjega zdravljenja ali smrti (TFST - time to first subsequent therapy or death) in časa do drugega nadaljnjega zdravljenja ali smrti (TSST - time to second subsequent therapy or death), ki je približek PFS2.
When olaparib is bound to the active site of DNA-associated PARP it prevents the dissociation of PARP and traps it on the DNA, thus blocking repair. 
Če je olaparib vezan na aktivno mesto z DNA povezane PARP, prepreči sprostitev PARP in jo ohrani vezano na DNA ter tako onemogoči popravilo.
In vitro, CYP3A4/5 were shown to be the enzymes primarily responsible for the metabolism of olaparib (see section 4.5). 
In vitro je dokazano, da so CYP3A4/5 encimi, ki so predvsem odgovorni za presnovo olapariba (glejte poglavje 4.5).
Of patients treated with Lynparza, who entered the study with evidence of disease (target or non-target lesions at baseline), 15.0% experienced complete response compared with 9.1% of patients on placebo. 
Med bolnicami, ki so prejemale zdravilo Lynparza in so v študijo vstopile z znaki bolezni (ciljne ali neciljne lezije izhodiščno), jih je popoln odziv doseglo 15,0 %, s placebom pa 9,1 %.
Both nausea and vomiting were reported to be intermittent for the majority of patients and can be managed by dose interruption, dose reduction and/or antiemetic therapy. 
Navzea in bruhanje sta bila pri večini bolnic intermitentna in ju je mogoče obvladati s prekinitvijo uporabe, zmanjšanjem odmerka in/ali uporabo antiemetikov.
Embryofoetal toxicity 
Embrio-fetalna toksičnost
Genetic counselling for patients tested for mutations in BRCA1/2 genes should be performed according to local regulations. 
Genetsko svetovanje bolnikom, testiranim za prisotnost mutacij v genih BRCA1/2, je treba opraviti v skladu z lokalnimi predpisi.
Therefore, it is recommended that patients take Lynparza at least one hour after food, and refrain from eating preferably for up to 2 hours afterwards (see section 4.2). 
Zato je priporočljivo, da bolnice jemljejo zdravilo Lynparza vsaj eno uro po jedi ter po možnosti ne smejo jesti do 2 uri po uporabi zdravila (glejte poglavje 4.2).
In a female fertility study where rats were dosed until implantation, although extended oestrus was observed in some animals, mating performance and pregnancy rate was not affected. 
V študiji plodnosti pri samicah, v kateri so podgane dobivale zdravilo do implantacije, so pri nekaterih živalih sicer opažali podaljšan estrus, a sposobnost parjenja in delež brejosti nista bila prizadeta.
The incidence of elevations in mean corpuscular volume from low or normal at baseline to above the ULN was approximately 55%. 
Pojavnost povečanj povprečnega volumna eritrocitov (MCV) od majhnega ali normalnega izhodiščno do MCV nad ZNM je bila približno 55 %.
• phenytoin, carbamazepine, phenobarbital - used as a sedative or to treat fits (seizures) and epilepsy 
• fenitoin, karbamazepin, fenobarbital - uporabljajo se kot pomirjevala ali za zdravljenje napadov krčev (epileptičnih napadov) in epilepsije,
Studies using human bone marrow cells also showed that direct exposure to olaparib can result in toxicity to bone marrow cells in ex vivo assays. 
Študije, v katerih so uporabili celice humanega kostnega mozga so tudi dokazale, da je ob neposredni izpostavljenosti celic kostnega mozga olaparibu v ex vivo poskusih lahko le ta zanje toksičen.
Lynparza is for oral use. 
Zdravilo Lynparza je za peroralno uporabo.
• ovarian cancer that has come back (recurred). 
• raka jajčnikov, ki se je ponovil.